Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HIV-1: early-phase trial registry
2 of 10 indexed HIV-1 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 2 currently recruiting · #1,724 of 28,707 conditions by registered trial count
HIV-1: 10 US clinical trials tracked, 2 recruiting.
HIV-1 is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 3 of these trials.
Enrollment posture brief
Registry condition hiv-1
OPEN 2 | RECR 20% | LATE 2 | EARLY 7 | RANK #1724 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acral Lentiginous Melanoma (20% recruiting · 5 trials)
HIV-1 lists 2 open slots (20% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for HIV-1 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
HIV-1 is recruiting below its size-band peers.
2 of 10 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates HIV-1 research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 3 of 10 trials (30%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most HIV-1 trials plan to enrol fewer than 100 people.
Median target enrolment is 48 among the 10 trials that report a genuine target (sentinel values excluded). 7 of those (70%) plan for fewer than 100 participants.
-
HIV-1 research is mostly interventional.
9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1
National Institute of Allergy and Infectious Diseases (NIAID)
NCT06517693
CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS
City of Hope Medical Center
NCT06252402
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants
Janssen Sciences Ireland UC
NCT00980538
A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05612178
TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
Tibotec Pharmaceuticals, Ireland
NCT00543725
Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial
Janssen-Cilag Pty
NCT01177059
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1
AbbVie
NCT04223804
Phase 1 Safety Study of Two Experimental HIV Vaccines
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00479999
Treatment De-Intensification and Residual HIV-1 in Youth
University of North Carolina, Chapel Hill
NCT00867854
Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets
Janssen Pharmaceutica N.V., Belgium
NCT04006704
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 1 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on HIV-1 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on HIV-1 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this HIV-1 page
10 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 HIV-1 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most HIV-1 trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HIV-1 condition card totals 10 registered trials; most-linked intervention OZ1 transduced cells; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.